WO1994012187A1 - Rectal flunisolide compositions for treating inflammatory intestinal disorders - Google Patents
Rectal flunisolide compositions for treating inflammatory intestinal disorders Download PDFInfo
- Publication number
- WO1994012187A1 WO1994012187A1 PCT/EP1993/003228 EP9303228W WO9412187A1 WO 1994012187 A1 WO1994012187 A1 WO 1994012187A1 EP 9303228 W EP9303228 W EP 9303228W WO 9412187 A1 WO9412187 A1 WO 9412187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic composition
- composition according
- flunisolide
- rectal
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Definitions
- the present invention relates to topical rectal therapeutic compositions containing, the as active ingredient, flunisolide and/or ester derivatives of same in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.
- flunisolide and/or ester derivatives of same in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.
- ulcerative colitis is certainly the best known. It essentially affects the large intestine, in particular and most severely the rectum, but sometimes, either marginally or entirely, the colon too.
- Other types of inflammatory intestinal diseases may affect the rectum and result in a mild ulcerative colitis or in a slightly different, but pathologically similar syndrome, such as proctitis and sigmoiditis.
- Another inflammatory intestinal disease is the so-called Crohn's disease, which affects the large intestine only marginally.
- a known treatment of the above pathologies consists in the systemic and topical administration of corticosteroids, such as hydrocortisone, betamethasone, and prednisolone.
- corticosteroids such as hydrocortisone, betamethasone, and prednisolone.
- the systemic administration of the aforesaid drugs produces serious side effects, mainly related to the interference with the hypothalamus-hypophysis-adrenal gland axis.
- corticosteroids causes interference with the hypothalamus-hypophysis-adrenal gland axis, since said drugs are inevitably absorbed by the systemic route.
- the side effects more frequently arising from the topical treatment of ulcerative colitis with the aforesaid traditional corticosteroids are: transient or prolonged depression of adrenal gland functionality, weight increase, acne, and facies lunaris .
- a characteristic of ulcerative colitis is an inflammed intestinal mucosa, which facilitates the systemic absorption of the drugs which are usually administered over an extended period of time. Therefore, the need of developing a corticosteroid exerting a high therapeutic activity in the treatment of inflammatory intestinal diseases and involving a reduced systemic absorption was deeply felt.
- Flunisolide is a corticosteroid having formula
- This molecule is characterized by not high absorption levels and by a metabolic process (hepatic first pass) which rapidly transforms same into the metabolite 6- ⁇ -hydroxyderivative, whose glucocorticoid activity is approx. 350 times lower than that of flunisolide.
- hepatic first pass hepatic first pass
- the amount of flunisolide inevitably absorbed by the systemic way after topical application can never reach plasma levels interfering with the hypothalamus-hypophysis- adrenal gland axis.
- the present invention It has surprisingly been found that flunisolide and its esters administered by the topical rectal way are very active in the treatment of the aforesaid intestinal disorders and - unlike the steroids known so far - do not cause the adverse effects related to the interference with the hypothalamus-hypophysis- adrenal gland axis.
- Object of the present invention is, therefore, a topical rectal therapeutic composition containing, as active ingredient, flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.
- the flunisolide used for the compositions of this invention is either anhydrous or in the corresponding hemihydrated form.
- flunisolide ester derivatives is used herein to mean the derivatives in which one or both hydroxylic functions in positions 11 and 21 of the aforesaid active ingredient have been esterified with C2-C20 alkyl-, aryl- or arylalkyl- mono and/or polycarboxylic acids, with alkyl- or aryl mono and/or polysulphonic acids, aryl acids containing one or more carboxylic functions and one or more sulphonic functions and, in case of carboxylic and/or sulphonic polyfunctional acids, the remaining acid functions are either partially or completely salified with pharmaceutically acceptable cations, preferably sodium, potassium, magnesium, calcium.
- pharmaceutically acceptable cations preferably sodium, potassium, magnesium, calcium.
- flunisolide esters are those formed with acetic acid, propionic acid, hexanoic acid, meta-sulfobenzoic acid and relative sodium meta-sulfobenzoate.
- compositions of the present invention are preferably in the form of enemas, suppositories, and foams.
- the suppositories of this invention contain from 0.5 to 10 mg each, preferably from 1 to 5 mg each of flunisolide and/or its ester derivatives.
- the suppositories of the present invention contain excipients preferably consisting of semisynthetic solid glycerides of vegetable saturated fatty acids.
- the rectal enemas of this invention are generally liquid compositions, solutions, emulsions or aqueous suspensions having an active ingredient content from 0.5 to 10 mg each, more preferably from 1 to 5 mg each, and generally containing preservatives, preferably selected among Parabens, chelating agents, such as for example ethylenediaminetetraacetic acid or the relative sodium salt.
- enemas be emulsions or suspensions, they would also contain thickeners, such as carboxymethylcellulose, and should they be solutions they would contain thickeners-solubilizers, such as propylene glycol. Said enemas may also contain compounds acting as pH regulators, preferably mineral or organic acids and/or pharmaceutically acceptable salts.
- the rectal foams have an active ingredient content preferably from 0.5 to 10 g/dose more preferably from 1 to 5 mg unitary dose.
- the rectal foams of this invention also contain: - traditional solubilizers , such as purified water and propylene glycol (the latter also acts as a thickener and is used for enemas) and solubilizers also protecting the skin, essentially consisting of partial glycerides of polyoxyethylenic saturated fatty acids;
- emulsifiers such as polysorbate 20 and mixtures of cetostearylic alcohol with sorbitan esterified with polyoxyethylenic fatty acids;
- - chelating agents such as ethylenediaminetetraacetic acid, also in the form of sodium salt;
- - acidifying buffers such as phosphoric acid and monobasic sodium or potassium phosphate
- propellants such as hydrocarbons, e.g. isobutane, or fluorocarbons, e.g. dichlorodifluoromethane and dichlorotetrafluoroethane, or hydrochlorofluorocarbons or hydrofluorocarbons.
- rectal foams - compared with enemas - have a lower water content and contain propellants, which are indispensable for dispensing the dose of drug to be administered.
- One l4-dose pressure bottle 2 mg hemihydrated flunisolide/dose
- one single-dose 2 mg hemihydrated flunisolide
- One l4-dose pressure bottle (2 mg hemihydrated flunisolide/dose) and one single-dose (2 mg hemihydrated flunisolide) pressure bottle contain: Multidose Single-dose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Topical rectal therapeutic composition containing, as the active ingredient, flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.
Description
RECTAL FLUNISOLIDE COMPOSITIONS FOR TREATING INFLAMMATORY INTESTINAL DISORDERS
Field of the invention The present invention relates to topical rectal therapeutic compositions containing, the as active ingredient, flunisolide and/or ester derivatives of same in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders. State of the art
Among all inflammatory intestinal diseases, ulcerative colitis is certainly the best known. It essentially affects the large intestine, in particular and most severely the rectum, but sometimes, either marginally or entirely, the colon too. Other types of inflammatory intestinal diseases may affect the rectum and result in a mild ulcerative colitis or in a slightly different, but pathologically similar syndrome, such as proctitis and sigmoiditis.
Another inflammatory intestinal disease is the so-called Crohn's disease, which affects the large intestine only marginally.
A known treatment of the above pathologies consists in the systemic and topical administration of corticosteroids, such as hydrocortisone, betamethasone, and prednisolone. However, the systemic administration of the aforesaid drugs
produces serious side effects, mainly related to the interference with the hypothalamus-hypophysis-adrenal gland axis.
Also the topical administration of said corticosteroids causes interference with the hypothalamus-hypophysis-adrenal gland axis, since said drugs are inevitably absorbed by the systemic route. The side effects more frequently arising from the topical treatment of ulcerative colitis with the aforesaid traditional corticosteroids are: transient or prolonged depression of adrenal gland functionality, weight increase, acne, and facies lunaris . It is to be noted that a characteristic of ulcerative colitis is an inflammed intestinal mucosa, which facilitates the systemic absorption of the drugs which are usually administered over an extended period of time. Therefore, the need of developing a corticosteroid exerting a high therapeutic activity in the treatment of inflammatory intestinal diseases and involving a reduced systemic absorption was deeply felt. Flunisolide is a corticosteroid having formula
H 3J'2
In fact, clinical trials carried out by the Applicant evidenced that an improvement of the basal symptomatology was obtained as early as after a 15-day topical rectal treatment at doses of 2 mg/die and that a 3-mg/die administration for 30 days did not cause any appreciable clinical modification to cortisol
plasmatic concentrations, an indicator of the interference, if any, with the hypothalamus-hypophysis-adrenal gland axis. Object of the present invention is, therefore, a topical rectal therapeutic composition containing, as active ingredient, flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders. Detailed description of the invention
The flunisolide used for the compositions of this invention is either anhydrous or in the corresponding hemihydrated form.
The expression "flunisolide ester derivatives" is used herein to mean the derivatives in which one or both hydroxylic functions in positions 11 and 21 of the aforesaid active ingredient have been esterified with C2-C20 alkyl-, aryl- or arylalkyl- mono and/or polycarboxylic acids, with alkyl- or aryl mono and/or polysulphonic acids, aryl acids containing one or more carboxylic functions and one or more sulphonic functions and, in case of carboxylic and/or sulphonic polyfunctional acids, the remaining acid functions are either partially or completely salified with pharmaceutically acceptable cations, preferably sodium, potassium, magnesium, calcium.
Particularly preferred flunisolide esters are those formed with acetic acid, propionic acid, hexanoic acid, meta-sulfobenzoic acid and relative sodium meta-sulfobenzoate.
The compositions of the present invention are preferably in the
form of enemas, suppositories, and foams.
The suppositories of this invention contain from 0.5 to 10 mg each, preferably from 1 to 5 mg each of flunisolide and/or its ester derivatives. In addition to the active ingredient, the suppositories of the present invention contain excipients preferably consisting of semisynthetic solid glycerides of vegetable saturated fatty acids. The rectal enemas of this invention are generally liquid compositions, solutions, emulsions or aqueous suspensions having an active ingredient content from 0.5 to 10 mg each, more preferably from 1 to 5 mg each, and generally containing preservatives, preferably selected among Parabens, chelating agents, such as for example ethylenediaminetetraacetic acid or the relative sodium salt. Should said enemas be emulsions or suspensions, they would also contain thickeners, such as carboxymethylcellulose, and should they be solutions they would contain thickeners-solubilizers, such as propylene glycol. Said enemas may also contain compounds acting as pH regulators, preferably mineral or organic acids and/or pharmaceutically acceptable salts.
The rectal foams have an active ingredient content preferably from 0.5 to 10 g/dose more preferably from 1 to 5 mg unitary dose. Preferably, the rectal foams of this invention also contain:
- traditional solubilizers , such as purified water and propylene glycol (the latter also acts as a thickener and is used for enemas) and solubilizers also protecting the skin, essentially consisting of partial glycerides of polyoxyethylenic saturated fatty acids;
- emulsifiers, such as polysorbate 20 and mixtures of cetostearylic alcohol with sorbitan esterified with polyoxyethylenic fatty acids;
- chelating agents, such as ethylenediaminetetraacetic acid, also in the form of sodium salt;
- preservatives, such as Parabens - also used for enemas;
- acidifying buffers, such as phosphoric acid and monobasic sodium or potassium phosphate;
- propellants, such as hydrocarbons, e.g. isobutane, or fluorocarbons, e.g. dichlorodifluoromethane and dichlorotetrafluoroethane, or hydrochlorofluorocarbons or hydrofluorocarbons.
As concerns the pharmaceutical formulation, rectal foams - compared with enemas - have a lower water content and contain propellants, which are indispensable for dispensing the dose of drug to be administered.
It is just the presence of propellants that allows the dose dispensed at each release of the pressure valve - in case of multidose bottles - or on pressure release valve - in case of single-dose bottles - to spread out and reach the inmost regions of the intestine, e.g. the colon left splenic flexure.
The propelling properties can vary depending on the type and quantity of propellant used and, consequently, the foam can reach more or less distant regions of the intestine. The following examples of therapeutic compositions for topical rectal use that are the object of this invention are conveyed by way of indication, not of limitation. A) Rectal foam
1) One 14-dose pressure bottle (2 mg anhydrous flunisolide/dose) and one single-dose (2 mg anhydrous flunisolide) pressure bottle contain:
Multidose Single-dose
Anhydrous flunisolide 28 mg 2 mg
Cetostearylic alcohol + sorbitan polyoxyethylenic esters 830 mg 59-3 mg
Polysorbate 20 553 mg 39-5 mg Propylene glycol 11.38 g 956 mg Glycerides of polyoxyethylenic saturated fatty acids 6.85 489 mg Purified water 10.17 g 726 mg
Methyl p-hydroxybenzoate 39-5 mg 2.8 mg Propyl p-hydroxybenzoate 7-9 mg O.56 mg Ethylenediaminetetraacetic acid disodium salt 15-8 mg 1.13 mg Monobasic sodium phosphate 313 mg 22 Λ mg
Phosphoric acid q. s . to pH
Dichlorodifluoromethane 2.53 S 616 mg
Dichlorotetrafluoroethane 3-79 B 22 mg
2 ) One l4-dose pressure bottle ( 2 mg hemihydrated flunisolide/dose ) and one single-dose ( 2 mg hemihydrated flunisolide) pressure bottle contain:
Multidose Single-dose
Hemihydrated flunisolide 28.58 mg 2.04 mg Cetostearylic alcohol + sorbitan polyoxyethylenic esters 830 mg 59-3 mg
Polysorbate 20 553 mg 39-5 mg
Propylene glycol 13.38 g 956 mg
Glycerides of polyoxyethylenic saturated fatty acids 6.85 g 489 mg
Purified water 10.17 g 726 mg
Methyl p-hydroxybenzoate 39.5 mg 2.8 mg
Propyl p-hydroxybenzoate 7-9 mg 0.56 mg
Ethylenediaminetetraacetic acid disodium salt 15.8 mg 1.13 mg
Monobasic sodium phosphate 313 mg 22.4 mg
Phosphoric acid q.s. to pH 5
Dichlorodifluoromethane 2.53 g 616 mg
Dichlorotetrafluoroethane 3-79 g 922 mg 3) One 14-dose pressure bottle (2 mg anhydrous flunisolide/dose) and one single-dose (2 mg anhydrous
flunisolide) pressure bottle contain:
Multidose Single-dose Anhydrous flunisolide 28 mg 2 mg Cetostearylic alcohol + sorbitan polyoxyethylenic esters 830 mg 59.3 m
Polysorbate 20 553 mg 39-5 mg
Propylene glycol 13-38 g 956 mg
Glycerides of polyoxyethylenic saturated fatty acids 6.85 g 489 mg Purified water 10.17 g 726 mg
Methyl p-hydroxybenzoate 39•5 mg 2.8 mg
Propyl p-hydroxybenzoate 7-9 mg O.56 mg
Ethylenediaminetetraacetic acid disodium salt I5.8 mg 1.13 mg
Monobasic sodium phosphate 313 mg 22.4 mg
Phosphoric acid q.s. to pH 5
Isobutane 3-16 g 769 mg
4) One l4-dose pressure bottle (2 mg hemihydrated flunisolide/dose) and one single-dose (2 mg hemihydrated flunisolide) pressure bottle contain:
Multidose Single-dose
Hemihydrated flunisolide 28.58 mg 2.04 mg
Cetostearylic alcohol + sorbitan polyoxyethylenic esters 830 mg 59.3 mg
Polysorbate 20 553 mg 39.5 mg
Propylene glycol 13-38 g 956 mg
Glycerides of polyoxyethylenic saturated fatty acids 6.85 g 489 mg Purified water 10.17 g 726 mg
Methyl p-hydroxybenzoate 39-5 mg 2.8 mg
Propyl p-hydroxybenzoate 7-9 mg O.56 mg
Ethylenediaminetetraacetic acid disodium salt 15-8 mg 1.13 mg Monobasic sodium phosphate 313 mg 22.4 mg
Phosphoric acid q.s. to pH
Isobutane 3-16 g 769 mg
B) Suppositories
5) One suppository (2 mg anhydrous flunisolide) contains: Anhydrous flunisolide 2 mg
Glyceric esters of saturated fatty acids 1498 mg
6) One suppository (2 mg hemihydrated flunisolide) contains: Hemihydrated flunisolide 2.04 mg Glyceric esters of saturated fatty acids 1498 mg
C) Enema
7) One 60 ml single-dose bottle (2 mg anhydrous flunisolide) contains:
Anhydrous flunisolide 2 mg propylene glycol 24 g
Ethylenediaminetetraacetic acid sodium salt 15 mg
Hydrochloric acid q. s . to pH 5
Purified water q. s . to 60 ml 8) One 60 ml single-dose bottle (2 mg hemihydrated flunisolide) contains:
Hemihydrated flunisolide 2.04 mg Propylene glycol 24 g
Ethylenediaminetetraacetic acid sodium salt 15 mg
Hydrochloric acid q.s. to pH 5
Purified water q.s. to 60 ml
The excipients of the above compositions are reported below. Rectal foam EXCIPIENT FUNCTION
- Cetostearyl alcohol containing sorbitan esterified with polyoxyethylenic fatty acids emulsifier
- Polysorbate 20 emulsifier - Partial glycerides of polyoxyethylenic
saturated fatty acids solubilizer-skin protector
- Propylene glycol solubilizer-thickener
- Methyl p-hydroxybenzoate sodium salt preservative
- Propyl p-hydroxybenzoate sodium salt preservative - Ethylenediaminetetraacetic acid disodium salt chelating agent
- Purified water solubilizing vehicle
- Monobasic sodium phosphate and phosphoric acid pH regulating buffer - Dichlorodifluoromethane propellant - Dichlorotetrafluoroethane propellant
- Isobutane propellant Suppository
EXCIPIENT FUNCTION - Semisynthetic solid glycerides mass for supporitory (solid vehicle)
Enema EXCIPIENT FUNCTION
- Propylene glycol solubilizer-thickener
- Ethylenediaminetetraacetic acid sodium salt chelating agent
- Hydrochloric acid acidifier
- Purified water solubilizing vehicle
CLINICAL TRIALS
FLUNISOLIDE ENEMA (2 and 3 mg) Preliminary clinical trials were conducted with Flunisolide in the form of enema using No. 18 patients of both sexes suffering from ulcerative colitis, limited to the splenic flexure. Patients were divided into two groups and treated with 2 mg/die and 3 mg/die, respectively, for 30 days.
The obtained results clearly indicate that the drug has an excellent therapeutic efficacy and above all is well tolerated, especially in relation to the inferference with the hypothalamus-hypophysis-adrenal gland axis.
In particular treatments with Flunisolide at a dose of 2 mg/die and 3 mg/die for 15 and 30 days always produced statistically significant improvements (Mann-Whitney's "U" test) of the basal sympotomatology as far as the clinical and the sigmoidoscopic parameters are concerned (cf. Table 1 attached hereto). As concerns drug toleration to the treatment and in particular the interference with the hypothalamus-hypophysis-adrenal gland axis, the treatment with flunisolide at the higher dose (3 mg/die) for 30 days never determined cortisolemia values below normality.
TABLE 1 Average values ± standard error of the mean of scores detected basally (TQ) and after 1 (T^) and 30 (T^Q) days of treatment with flunisolide at the dose of 2 and 3 mg/die. Results of the statistical evaluation made by Mann-Whitney's "U" test compared with the respective basal values, (score 1 = normal; score 2 = mild; score 3 = moderate)
Flunisolide 2 mg/die (No. 10) PARAMETERS TQ T15 T3Q
CLINICAL 2.7 ± 0.2 1.9 ± 0.2 1.5 ± 0.2
SIGMOIDOSCOPIC 2.7 ± 0.2 2.2 ± 0.1 1.6 ± 0.2
#*
Flunisolide 3 mg/die (No. 8)
PARAMETERS T0 T15 T30 CLINICAL 2.9 ± 0.1 2.0 ± 0.2 1.6 ± 0.2
SIGMOIDOSCOPIC 3.0 2.4 ± 0.2 2.1 ± 0.2
P ≤ 0.05; ** P ≤ 0.01
Claims
CLAIMS 1. Topical rectal therapeutic composition containing, as active ingredient, anhydrous or hemihydrated flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders. 2. The therapeutic composition according to claim 1 wherein "flunisolide ester derivatives" are those having one or both hydroxylic functions in positions 11 and 21 of the aforesaid active ingredient esterified with C2-C2 alkyl-, aryl- or arylalkyl- mono and/or polycarboxylic acids, with alkyl- or aryl mono and/or polysulphonic acids, aryl acids containing one or more carboxylic functions and one or more sulphonic functions and, in case of carboxylic and/or sulphonic polyfunctional acids, the remaining acid functions are either partially or completely salified with pharmaceutically acceptable cations. 3- The therapeutic composition according to claim 2 wherein the flunisolide esters are the esters formed with acetic acid, propionic acid, hexanoic acid, meta-sulfobenzoic acid and relevant sodium meta-sulfobenzoate. 4. The therapeutic composition according to claim 1 wherein said composition is in the suppository form and has an active ingredient content of from 0.5 to 10 mg. 5- The therapeutic composition according to claim 4 wherein said composition contains excipients consisting of
semisynthetic glycerides of vegetable saturated fatty acids. 6. The therapeutic composition according to claim 1 wherein said composition is in the rectal enema form. 7- The therapeutic composition according to claim 6 wherein said rectal enema is a solution, an emulsion or an aqueous suspension, and has an active ingredient content from 0.5 to 10 mg/ unitary dose. 8. The therapeutic composition according to claim 6 wherein said composition also contains preservatives and chelating agents; should said enemas be emulsions or suspensions, they would also contain thickeners-emulsifiers and should they be solutions they would contain thickeners-solubilizers and pH regulators. 9- The therapeutic composition according to claim 1 wherein said composition is in the rectal foam form. 10. The therapeutic composition according to claim 9 wherein said rectal foam has an active ingredient content of from 0.5 to 10 mg/ unitary dose. 11. The therapeutic composition according to claim 9 wherein said composition contains, in addition to the active ingredient, emulsifiers, water, thickeners-solubilizers, and thickeners-solubilizers also exerting a skin protective action, preservatives, chelating agents, acidifying buffers, and propellants. 12. The therapeutic composition according to claim 1 for the
treatment of ulcerative colitis, of inflammatory intestinal diseases resulting in a mild ulcerative colitis or in a slightly different, but pathologically similar syndrome, such as proctitis and sigmoiditis, and of Crohn's disease.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002149766A CA2149766C (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide compositions for treating inflammatory intestinal disorders |
| EP94901816A EP0804203B1 (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide compositions for treating inflammatory intestinal disorders |
| AU56251/94A AU5625194A (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide compositions for treating inflammatory intestinal disorders |
| DE69328205T DE69328205T2 (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide preparation for the treatment of inflammatory bowel diseases |
| US08/436,291 US5721228A (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide compositions for treating inflammatory intestinal disorders |
| AT94901816T ATE190845T1 (en) | 1992-11-20 | 1993-11-18 | RECTAL FLUNISOLIDE PREPARATION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI92A002657 | 1992-11-20 | ||
| ITMI922657A IT1256061B (en) | 1992-11-20 | 1992-11-20 | THERAPEUTIC COMPOSITION FOR RECTAL USE BASED ON FLUNISOLIDE AND / OR FOREIGN DEIRELATIVES FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994012187A1 true WO1994012187A1 (en) | 1994-06-09 |
Family
ID=11364319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1993/003228 Ceased WO1994012187A1 (en) | 1992-11-20 | 1993-11-18 | Rectal flunisolide compositions for treating inflammatory intestinal disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5721228A (en) |
| EP (1) | EP0804203B1 (en) |
| AT (1) | ATE190845T1 (en) |
| AU (1) | AU5625194A (en) |
| CA (1) | CA2149766C (en) |
| DE (1) | DE69328205T2 (en) |
| IT (1) | IT1256061B (en) |
| WO (1) | WO1994012187A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145067A1 (en) * | 2013-03-15 | 2014-09-18 | Medicis Pharmaceutical Corporation | Topical compositions of flunisolide and methods of treatment |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY113046A (en) * | 1994-03-22 | 2001-11-30 | Astrazeneca Uk Ltd | Pharmaceutical compositions |
| US20070071779A1 (en) * | 2005-09-26 | 2007-03-29 | Leggit Ingenuity, Llc | Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0278174A2 (en) * | 1986-12-24 | 1988-08-17 | Glaxo Group Limited | Use of fluticasone propionate in the preparation of a pharmaceutical composition for the treatment of bowel diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3124571A (en) * | 1964-03-10 | Process for hydrgxyiation of | ||
| JPS56135416A (en) * | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
| US4552872A (en) * | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
-
1992
- 1992-11-20 IT ITMI922657A patent/IT1256061B/en active IP Right Grant
-
1993
- 1993-11-18 DE DE69328205T patent/DE69328205T2/en not_active Expired - Fee Related
- 1993-11-18 WO PCT/EP1993/003228 patent/WO1994012187A1/en not_active Ceased
- 1993-11-18 AT AT94901816T patent/ATE190845T1/en not_active IP Right Cessation
- 1993-11-18 EP EP94901816A patent/EP0804203B1/en not_active Expired - Lifetime
- 1993-11-18 US US08/436,291 patent/US5721228A/en not_active Expired - Fee Related
- 1993-11-18 AU AU56251/94A patent/AU5625194A/en not_active Abandoned
- 1993-11-18 CA CA002149766A patent/CA2149766C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0278174A2 (en) * | 1986-12-24 | 1988-08-17 | Glaxo Group Limited | Use of fluticasone propionate in the preparation of a pharmaceutical composition for the treatment of bowel diseases |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE MEDLINE Dialog Information Services, File 155; "Accession Number 04698528" * |
| TAKAI ET AL.: "The predominance of flunisolide in the topical use of anti-inflammatory steroids", J. PHARMACOBIODYN., vol. 5, no. 3, 1982, pages 200 - 207 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145067A1 (en) * | 2013-03-15 | 2014-09-18 | Medicis Pharmaceutical Corporation | Topical compositions of flunisolide and methods of treatment |
| US10953021B2 (en) | 2013-03-15 | 2021-03-23 | Lupin Limited | Topical compositions of flunisolide and methods of treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE190845T1 (en) | 2000-04-15 |
| IT1256061B (en) | 1995-11-23 |
| EP0804203B1 (en) | 2000-03-22 |
| CA2149766C (en) | 2005-07-26 |
| EP0804203A1 (en) | 1997-11-05 |
| DE69328205D1 (en) | 2000-04-27 |
| ITMI922657A1 (en) | 1994-05-20 |
| CA2149766A1 (en) | 1994-06-09 |
| US5721228A (en) | 1998-02-24 |
| DE69328205T2 (en) | 2000-11-09 |
| ITMI922657A0 (en) | 1992-11-20 |
| AU5625194A (en) | 1994-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1085877B1 (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma | |
| EP0871450A1 (en) | New combination | |
| US5149694A (en) | Combination of tobramycin and dexamethasone for topical ophthalmic use | |
| WO1990001933A1 (en) | Combination of quinolone antibiotics and steroids for topical ophthalmic use | |
| IE65336B1 (en) | Use of the active substance azelastine in the treatment of psoriasis diseases | |
| US20050192357A1 (en) | Pharmaceuticals for xerosis | |
| US20080261930A1 (en) | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | |
| US5721228A (en) | Rectal flunisolide compositions for treating inflammatory intestinal disorders | |
| US5149693A (en) | Combination of tobramycin and fluorometholone for topical ophthalmic use | |
| EP1527781B1 (en) | Antipruritic agent | |
| US7390796B2 (en) | Fatty acid modified forms of glucocorticoids | |
| JP2749778B2 (en) | Triamcinolone derivative | |
| US4374856A (en) | Liver cytoprotection using PGE's | |
| US7018995B2 (en) | Carbonate and carbamate modified forms of glucocorticoids | |
| RU2223097C1 (en) | Combined preparation for treating skin diseases | |
| WO2003097070A1 (en) | The pharmaceutical composition comprising a corticosteroid and an antiseptic | |
| RU2223765C1 (en) | Anti-inflammatory and anti-allergic composition | |
| HK1035145B (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma | |
| HK1089691B (en) | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids | |
| HK1152252A (en) | Therapeutic use on-demand of formoterol and budesonide | |
| HK1089690B (en) | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | |
| JPS6220197B2 (en) | ||
| JPS6040440B2 (en) | prednisolone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NZ US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 08436291 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2149766 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1994901816 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994901816 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1994901816 Country of ref document: EP |